Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd has announced successful Phase I/II clinical trial results for RECCE® 327, an intravenous treatment for urinary tract infections and urosepsis. The trial confirmed the drug’s efficacy in controlling bacterial growth, particularly E. coli, without any serious adverse events, suggesting a good safety profile. The optimal dosing regimen was established and a Phase II trial is expected to commence in the second half of 2024.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
